What is Leerink Partnrs’ Estimate for LVTX Q1 Earnings?

LAVA Therapeutics (NASDAQ:LVTX) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for LAVA Therapeutics in a report issued on Thursday, December 12th. Leerink Partnrs analyst D. Graybosch forecasts that the company will earn ($0.23) per share for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.28) per share. Leerink Partnrs also issued estimates for LAVA Therapeutics’ Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.22) EPS and Q4 2025 earnings at ($0.23) EPS.

Other equities analysts have also issued research reports about the stock. Citizens Jmp lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. JMP Securities reiterated a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Finally, Leerink Partners restated a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, LAVA Therapeutics currently has a consensus rating of “Hold” and an average target price of $4.67.

LAVA Therapeutics Price Performance

LAVA Therapeutics stock opened at $1.02 on Monday. LAVA Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.47. The firm has a market capitalization of $25.86 million, a price-to-earnings ratio of -0.99 and a beta of 0.43. The company’s 50 day simple moving average is $1.67 and its 200 day simple moving average is $1.81.

Institutional Trading of LAVA Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Pathway Financial Advisors LLC lifted its stake in LAVA Therapeutics by 328.6% in the 2nd quarter. Pathway Financial Advisors LLC now owns 60,000 shares of the company’s stock valued at $108,000 after acquiring an additional 46,000 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of LAVA Therapeutics in the second quarter valued at approximately $55,000. Finally, Virtu Financial LLC bought a new stake in shares of LAVA Therapeutics in the third quarter worth $32,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.